Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of SERENADE with macitentan in HFpEF and pulmonary vascular disease
2018-001603-37Phase 2Terminated
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of macitentan in heart failure with preserved ejection fraction (HFpEF) and pulmonary vascular disease (PVD), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Long-term safety of macitentan 10 mg. Started Apr 2019; status: terminated.
02
Drugs
macitentan
03
Conditions
heart failure with preserved ejection fraction (HFpEF)pulmonary vascular disease (PVD)
Beyond the preview
Go deeper on 2018-001603-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001603-37.